
Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 6, 17, 2, 27, 13 and 2 respectively.
Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 6, 17, 2, 27, 13 and 2 respectively.
Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
155 Pages
- Introduction
- Global Markets Direct Report Coverage
- Psoriatic Arthritis – Overview
- Psoriatic Arthritis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Psoriatic Arthritis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Psoriatic Arthritis – Companies Involved in Therapeutics Development
- 3SBio Inc
- AbbVie Inc
- Acelyrin Inc
- Aclaris Therapeutics Inc
- Alpine Immune Sciences Inc
- AltruBio Inc
- Alvotech SA
- Amgen Inc
- Avesthagen Ltd
- Avotres Inc
- Azora Therapeutics Australia Pty Ltd
- Bio-Thera Solutions Ltd
- Biocad
- Biocon Ltd
- Biogen Inc
- BiondVax Pharmaceuticals Ltd
- BiosanaPharma BV
- Bioviz Technologies Pvt Ltd
- BioXpress Therapeutics SA
- Bristol-Myers Squibb Co
- Cantargia AB
- Celltrion Inc
- Celon Pharma SA
- DM Bio Ltd
- DNX Biopharmaceuticals Inc
- Dong-A ST Co Ltd
- Eli Lilly and Co
- f5 Therapeutics Inc
- Formycon AG
- Galapagos NV
- Huabo Biopharm (Shanghai) Co Ltd
- Immunwork Inc
- Innovimmune Biotherapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- Kangpu Biopharmaceuticals Ltd
- Luye Pharma Group Ltd
- Mabpharm Ltd
- Machavert Pharmaceuticals LLC
- Microba Life Sciences Ltd
- MoonLake Immunotherapeutics
- Mycenax Biotech Inc
- NeuClone Pty Ltd
- Nimbus Therapeutics LLC
- Novartis AG
- Pfizer Inc
- Pharmapraxis
- Polpharma Biologics SA
- Protein Foundry LLC
- Rani Therapeutics LLC
- Sagacity pharmaceuticals
- Samsung Bioepis Co Ltd
- Sandoz International GmbH
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Siam Bioscience Co Ltd
- Sun Pharma Advanced Research Company Ltd
- SynAct Pharma AB
- UCB SA
- Vascular Biogenics Ltd
- Ventyx Biosciences Inc
- XBiotech Inc
- XinThera Inc
- Psoriatic Arthritis – Drug Profiles
- AbGn-168H – Drug Profile
- acazicolcept – Drug Profile
- adalimumab biosimilar – Drug Profile
- AP-1189 – Drug Profile
- apremilast – Drug Profile
- AT-193 – Drug Profile
- Autoimmune Diseases – Drug Profile
- AVT-001 – Drug Profile
- bimekizumab – Drug Profile
- Bmab-1200 – Drug Profile
- CAN-10 – Drug Profile
- CC-99677 – Drug Profile
- certolizumab pegol biosimilar – Drug Profile
- CNTO-6785 – Drug Profile
- DA-5215 – Drug Profile
- deucravacitinib – Drug Profile
- DNX-114 – Drug Profile
- DNX-514 – Drug Profile
- etanercept – Drug Profile
- etanercept biosimilar – Drug Profile
- GLPG-3667 – Drug Profile
- GLPG-4399 – Drug Profile
- golimumab biosimilar – Drug Profile
- guselkumab – Drug Profile
- HB-0017 – Drug Profile
- infliximab biosimilar – Drug Profile
- INV-17 – Drug Profile
- ivarmacitinib sulfate – Drug Profile
- ixekizumab – Drug Profile
- izokibep – Drug Profile
- JNJ-4804 – Drug Profile
- KPG-612 – Drug Profile
- Live Bacteria Product (LBP) Candidates – Drug Profile
- MK2 Backup – Drug Profile
- MP-1115 – Drug Profile
- NanoAbs targeting IL-17A, IL-17F and IL-17A/F Complex – Drug Profile
- NDI-034858 – Drug Profile
- netakimab – Drug Profile
- PI3K Delta Inhibitors – Drug Profile
- QX-002N – Drug Profile
- Recombinant Protein to Antagonize CCR6 for Psoriasis – Drug Profile
- RHE-70202 – Drug Profile
- risankizumab – Drug Profile
- RT-105 – Drug Profile
- secukinumab – Drug Profile
- secukinumab biosimilar – Drug Profile
- Small Molecules 2 for Musculoskeletal, Gastrointestinal and Autoimmune Disorders – Drug Profile
- Small Molecules for Musculoskeletal, Gastrointestinal and Autoimmune Disorders – Drug Profile
- sonelokimab – Drug Profile
- SSGJ-608 – Drug Profile
- TE-2122 – Drug Profile
- TE-2158 – Drug Profile
- tildrakizumab – Drug Profile
- tofacitinib citrate – Drug Profile
- upadacitinib ER – Drug Profile
- ustekinumab – Drug Profile
- ustekinumab biosimilar – Drug Profile
- VB-601 – Drug Profile
- VTX-958 – Drug Profile
- vunakizumab – Drug Profile
- WXSH-0408 – Drug Profile
- XIN-005404 – Drug Profile
- zunsemetinib – Drug Profile
- Psoriatic Arthritis – Dormant Projects
- Psoriatic Arthritis – Discontinued Products
- Psoriatic Arthritis – Product Development Milestones
- Featured News & Press Releases
- Sep 26, 2022: MoonLake Immunotherapeutics to initiate global phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis
- Sep 12, 2022: Cosentyx 300 mg Pen Approved in Japan: Novartis
- Sep 10, 2022: AbbVie showcases new analyses and real-world data across multiple immune-mediated skin diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress
- Sep 10, 2022: New late-breaking results from phase 3 trials of SKYRIZI (risankizumab) evaluating long-term effect on skin and joint symptoms in patients with psoriatic arthritis at Week 100
- Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting
- Aug 15, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022
- Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95
- Aug 02, 2022: US FDA grants approval for Janssen’s Stelara to treat psoriatic arthritis
- Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
- Jun 04, 2022: New data show patients treated with first-in-Class TREMFYA (guselkumab) achieve durable efficacy across joint and axial Symptoms of active psoriatic arthritis through two years
- Jun 03, 2022: ACELYRIN, Affibody and Inmagene Biopharmaceuticals announce data from global phase 2 trial of Izokibep in patients with psoriatic arthritis presented during 2022 European Alliance of Associations for Rheumatology Congress
- May 23, 2022: UCB announces first detailed data from two phase 3 bimekizumab studies in psoriatic arthritis to be presented at EULAR 2022
- May 18, 2022: New data show TREMFYA (guselkumab) binds to both inflammatory cells and interleukin (IL)-23, supporting a hypothesis for a differentiated mechanism from Risankizumab
- May 16, 2022: Alvotech announces positive results from a pharmacokinetic similarity study for AVT04, a proposed biosimilar to Stelara
- May 12, 2022: Amgen and Lance bBass partner to encourage people to do a 'double take' to recognize the early signs of psoriatic arthritis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Psoriatic Arthritis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Companies, 2022 (Contd..4)
- Table 11: Products under Development by Companies, 2022 (Contd..5)
- Table 12: Number of Products by Stage and Target, 2022
- Table 13: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 14: Number of Products by Stage and Mechanism of Action, 2022
- Table 15: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 16: Number of Products by Stage and Route of Administration, 2022
- Table 17: Number of Products by Stage and Molecule Type, 2022
- Table 18: Psoriatic Arthritis – Pipeline by 3SBio Inc, 2022
- Table 19: Psoriatic Arthritis – Pipeline by AbbVie Inc, 2022
- Table 20: Psoriatic Arthritis – Pipeline by Acelyrin Inc, 2022
- Table 21: Psoriatic Arthritis – Pipeline by Aclaris Therapeutics Inc, 2022
- Table 22: Psoriatic Arthritis – Pipeline by Alpine Immune Sciences Inc, 2022
- Table 23: Psoriatic Arthritis – Pipeline by AltruBio Inc, 2022
- Table 24: Psoriatic Arthritis – Pipeline by Alvotech SA, 2022
- Table 25: Psoriatic Arthritis – Pipeline by Amgen Inc, 2022
- Table 26: Psoriatic Arthritis – Pipeline by Avesthagen Ltd, 2022
- Table 27: Psoriatic Arthritis – Pipeline by Avotres Inc, 2022
- Table 28: Psoriatic Arthritis – Pipeline by Azora Therapeutics Australia Pty Ltd, 2022
- Table 29: Psoriatic Arthritis – Pipeline by Bio-Thera Solutions Ltd, 2022
- Table 30: Psoriatic Arthritis – Pipeline by Biocad, 2022
- Table 31: Psoriatic Arthritis – Pipeline by Biocon Ltd, 2022
- Table 32: Psoriatic Arthritis – Pipeline by Biogen Inc, 2022
- Table 33: Psoriatic Arthritis – Pipeline by BiondVax Pharmaceuticals Ltd, 2022
- Table 34: Psoriatic Arthritis – Pipeline by BiosanaPharma BV, 2022
- Table 35: Psoriatic Arthritis – Pipeline by Bioviz Technologies Pvt Ltd, 2022
- Table 36: Psoriatic Arthritis – Pipeline by BioXpress Therapeutics SA, 2022
- Table 37: Psoriatic Arthritis – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 38: Psoriatic Arthritis – Pipeline by Cantargia AB, 2022
- Table 39: Psoriatic Arthritis – Pipeline by Celltrion Inc, 2022
- Table 40: Psoriatic Arthritis – Pipeline by Celon Pharma SA, 2022
- Table 41: Psoriatic Arthritis – Pipeline by DM Bio Ltd, 2022
- Table 42: Psoriatic Arthritis – Pipeline by DNX Biopharmaceuticals Inc, 2022
- Table 43: Psoriatic Arthritis – Pipeline by Dong-A ST Co Ltd, 2022
- Table 44: Psoriatic Arthritis – Pipeline by Eli Lilly and Co, 2022
- Table 45: Psoriatic Arthritis – Pipeline by f5 Therapeutics Inc, 2022
- Table 46: Psoriatic Arthritis – Pipeline by Formycon AG, 2022
- Table 47: Psoriatic Arthritis – Pipeline by Galapagos NV, 2022
- Table 48: Psoriatic Arthritis – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
- Table 49: Psoriatic Arthritis – Pipeline by Immunwork Inc, 2022
- Table 50: Psoriatic Arthritis – Pipeline by Innovimmune Biotherapeutics Inc, 2022
- Table 51: Psoriatic Arthritis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 52: Psoriatic Arthritis – Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
- Table 53: Psoriatic Arthritis – Pipeline by Johnson & Johnson, 2022
- Table 54: Psoriatic Arthritis – Pipeline by Kangpu Biopharmaceuticals Ltd, 2022
- Table 55: Psoriatic Arthritis – Pipeline by Luye Pharma Group Ltd, 2022
- Table 56: Psoriatic Arthritis – Pipeline by Mabpharm Ltd, 2022
- Table 57: Psoriatic Arthritis – Pipeline by Machavert Pharmaceuticals LLC, 2022
- Table 58: Psoriatic Arthritis – Pipeline by Microba Life Sciences Ltd, 2022
- Table 59: Psoriatic Arthritis – Pipeline by MoonLake Immunotherapeutics, 2022
- Table 60: Psoriatic Arthritis – Pipeline by Mycenax Biotech Inc, 2022
- Table 61: Psoriatic Arthritis – Pipeline by NeuClone Pty Ltd, 2022
- Table 62: Psoriatic Arthritis – Pipeline by Nimbus Therapeutics LLC, 2022
- Table 63: Psoriatic Arthritis – Pipeline by Novartis AG, 2022
- Table 64: Psoriatic Arthritis – Pipeline by Pfizer Inc, 2022
- Table 65: Psoriatic Arthritis – Pipeline by Pharmapraxis, 2022
- Table 66: Psoriatic Arthritis – Pipeline by Polpharma Biologics SA, 2022
- Table 67: Psoriatic Arthritis – Pipeline by Protein Foundry LLC, 2022
- Table 68: Psoriatic Arthritis – Pipeline by Rani Therapeutics LLC, 2022
- Table 69: Psoriatic Arthritis – Pipeline by Sagacity pharmaceuticals, 2022
- Table 70: Psoriatic Arthritis – Pipeline by Samsung Bioepis Co Ltd, 2022
- Table 71: Psoriatic Arthritis – Pipeline by Sandoz International GmbH, 2022
- Table 72: Psoriatic Arthritis – Pipeline by Shanghai Henlius Biotech Inc, 2022
- Table 73: Psoriatic Arthritis – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
- Table 74: Psoriatic Arthritis – Pipeline by Siam Bioscience Co Ltd, 2022
- Table 75: Psoriatic Arthritis – Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
- Table 76: Psoriatic Arthritis – Pipeline by SynAct Pharma AB, 2022
- Table 77: Psoriatic Arthritis – Pipeline by UCB SA, 2022
- Table 78: Psoriatic Arthritis – Pipeline by Vascular Biogenics Ltd, 2022
- Table 79: Psoriatic Arthritis – Pipeline by Ventyx Biosciences Inc, 2022
- Table 80: Psoriatic Arthritis – Pipeline by XBiotech Inc, 2022
- Table 81: Psoriatic Arthritis – Pipeline by XinThera Inc, 2022
- Table 82: Psoriatic Arthritis – Dormant Projects, 2022
- Table 83: Psoriatic Arthritis – Dormant Projects, 2022 (Contd..1)
- Table 84: Psoriatic Arthritis – Dormant Projects, 2022 (Contd..2)
- Table 85: Psoriatic Arthritis – Dormant Projects, 2022 (Contd..3)
- Table 86: Psoriatic Arthritis – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Psoriatic Arthritis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.